QUEST DIAGNOSTICS INC News
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
see moreQUEST DIAGNOSTICS INC Market News
15d
Quest DGX Names Strategy Chief; M&A Focused Update
- Quest Diagnostics appointed Benjamin Beauvalot as Chief Strategy & M&A Officer, signaling renewed acquisition focus. Coupled with peer Labcorp's raised guidance and shifting specialty diagnostics activity, the move reshapes near-term expectations for DGX around dealmaking, margin management, and competitive positioning.
22d
Quest Diagnostics Rally: Q1 Beat Lifts PTs to $245
Quest Diagnostics (DGX) delivered a strong Q1 2026 quarter with revenue and EPS beats and raised guidance, prompting multiple analyst price-target increases and fresh institutional buying. Concrete earnings and capital-markets moves are reshaping near-term sentiment for the stock.
29d
DGX: Institutional Buys, Notes, AI Growth Push Now
Recent week developments for Quest Diagnostics (DGX) include institutional purchases, a $500M senior note issuance, accelerating adoption of its AI Companion tool, progress on Project Nova, and expansion of the Co‑Lab partnership with Corewell Health—moves that improve liquidity, operational efficiency, and growth runway.
04 May at 04:30
DGX: $500M 5.00% Notes Priced; Major Holder Cuts!!
Quest Diagnostics (DGX) priced a $500 million senior note due 2036 at a 5.00% coupon and plans to close the offering May 6, 2026. The move lengthens financing and may refinance near-term maturities against a ~ $6.4B debt load. Separately, institutional investor Cwm LLC trimmed its DGX stake by 28.4%—an ownership shift that could influence near-term stock flows. This article explains the concrete implications for DGX's balance sheet, credit profile, and shareholder signals.
27 Apr at 04:30
Quest Diagnostics Q1 Beat Fuels Bullish DGX Rally.
Quest Diagnostics reported a stronger-than-expected Q1 with revenue of $2.90B, raised full‑year guidance, and saw multiple analyst price‑target upgrades—driving notable upside in DGX shares. Operational gains from advanced diagnostics, AI adoption and productivity initiatives underpinned the result.
20 Apr at 04:30
Quest Diagnostics (DGX): Quiet Week, Watchlist Tip
No material news for Quest Diagnostics (DGX) in the past week. This briefing summarizes the lack of fresh catalysts, recalls key prior developments (dividend increase, buyback, recent earnings/guidance), and lists practical watchpoints — upcoming earnings timing, reimbursement policy, and tech/M&A activity — that could move the stock.
06 Apr at 04:30
Quest Diagnostics Q4 Beat Lifts DGX Shares 15% YTD
Quest Diagnostics reported a Q4 revenue and EPS beat with raised 2026 guidance, driving a double-digit surge in DGX shares. The results reflect stronger test volumes, higher-value diagnostics, and improved margins—key near-term catalysts for investors.